Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete If Known Substitute for form 1449B/PTO 10/509,940 Application Number INFORMATION DISCLOSURE June 3, 2005 Filing Date STATEMENT BY APPLICANT Peter K. LAW First Named Inventor 1633 Art Unit Ileana Popa (Use as many sheets as necessary) Examiner Name LAW.020.0002.PC Attorney Docket Number Sheet

	•		NON PATENT LITERATURE DOCUMENTS			
		Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  SUZUKI, K. et al. Cell Transplantation for the Treatment of Acute Myocardial Infarction Using Vascular Endothelial Growth Factor-Expressing Skeletal Myoblasts. Circulation. 18 September 2001, Vol.104, [suppl 1]. Pages 1-207-1-212			
		1				
T		2	POWELL, C. et al. Tissue-Engineered Human Bioartificial Muscles Muscles Expressing a Foreign Recombinant Protein for Gene Therapy, Human Gene Therapy. 01 March 1999, Vol. 10, No.4, pages 565-577			
7		3	LAWRENCE F. BROWN et al., "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) by Epidermal Keratinocytes during Wound Healing", J. Exp. Med., November 1992, pp.1376-1379, Vol. 176			
_		4	PETER LAW et al., "Myoblast transfer as a platform technology of gene therapy", Gene Therapy and Molecular Biology, March 1998, pp.345-363, Vol.1			
		5	PETER K. LAW, "The Regenerative Heart", Business Briefing: Pharmatech 2002, p.85-71			
<b> </b> 		/ 6	LAW, P. et al., "World's First Human Myoblast Transfer into the Heart", Frontiers in Physiology, August 16-19, 2000, Joint Meeting, Stockholm, Sweden			
•						
	•					
		-				

Examiner Signature	/Ileana Popa/	Date Considered	06/02/2007

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND INFORMATION THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450. Alexandria. VA 22313-FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for Use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1	449A/PTO		Complete if Known			
		Application Number	Unassigned			
INFORMA'	TION DISCLOSURE	Filing Date	Concurrently Herewith			
STATEME	NT BY APPLICANT	First Named Inventor	Peter K. LAW			
		Group Art Unit	Unassigned			
(use as i	many sheets as necessary)	Examiner Name	Unassigned			
Sheet 1	of 1	Attorney Docket Number	37794-0042			

U.S. PATENT DOCUMENTS							
Evaminar	Cite	Document Number		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan	
Examiner Initials *	No.1	Number - Kind Code² (if	known)	MM-DD-YYYY	or ones bocurrent	Passages or Relevant Figures Appear	
/117/	A01	6,261,832	B1	7/17/2001	LAW		
	<u> </u>		<del></del>				
						10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	

	FOREIGN PATENT DOCUMENTS								
Exarminer Initials*	Cite No.	Foreign Patent Document  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>©</sup>			
				·					

Date Considered /Ileana Popa/ Examiner 06/02/2007 Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.